Ginsenoside Rd

Ginsenoside Rd

• CAS Number: 52705-93-8
• UNSPSC Description: Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
• Target Antigen: Calcium Channel; COX; Cytochrome P450; Endogenous Metabolite; NF-κB
• Type: Natural Products
• Related Pathways: Immunology/Inflammation;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;NF-κB
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Ginsenoside-Rd.html
• Purity: 99.88
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: C[C@](CC/C=C(C)/C)([C@]1([H])[C@]([C@H](O)C[C@@]2([H])[C@@]3(C)CC[C@]4([H])[C@]2(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C4(C)C)([H])[C@@]3(C)CC1)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O
• Molecular Weight: 947.15
• References & Citations: [1]Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52.|[2]Lu C, et al. Inhibition of L-type Ca²⁺ current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77.|[3]Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc^Min/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.|[4]Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported